Micro Cap Bid Up Aggressively On FDA Clearance Announcement

By: Tomas Ronolski - AllPennyStocks.com News

Monday, May 19, 2025

A New York-based biotech company is already turning heads during Monday’s premarket hours after it was announced that the company received FDA clearance to initiate its phase 3b trial of its NurOwn for treatment of ALS, according to a press release this morning.

Traders wasted no time buying up shares of Brainstorm Cell Therapeutics Inc. (Nasdaq:BCLI), with shares of the micro cap currently bid up at $1.74/share (+31.82% implied open for sellers) at the time of writing. This should be an exciting session for this biotech!

Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.

Copyright © 2025 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.